365 related articles for article (PubMed ID: 21734466)
1. Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries.
Giaquinto C; Dominiak-Felden G; Van Damme P; Myint TT; Maldonado YA; Spoulou V; Mast TC; Staat MA
Hum Vaccin; 2011 Jul; 7(7):734-48. PubMed ID: 21734466
[TBL] [Abstract][Full Text] [Related]
2. Impact and effectiveness of RotaTeq® vaccine based on 3 years of surveillance following introduction of a rotavirus immunization program in Finland.
Vesikari T; Uhari M; Renko M; Hemming M; Salminen M; Torcel-Pagnon L; Bricout H; Simondon F
Pediatr Infect Dis J; 2013 Dec; 32(12):1365-73. PubMed ID: 24051998
[TBL] [Abstract][Full Text] [Related]
3. Pentavalent rotavirus vaccine (RotaTeq): a review of its use in the prevention of rotavirus gastroenteritis in Europe.
Plosker GL
Drugs; 2010 Jun; 70(9):1165-88. PubMed ID: 20518582
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial.
Iwata S; Nakata S; Ukae S; Koizumi Y; Morita Y; Kuroki H; Tanaka Y; Shizuya T; Schödel F; Brown ML; Lawrence J
Hum Vaccin Immunother; 2013 Aug; 9(8):1626-33. PubMed ID: 23732903
[TBL] [Abstract][Full Text] [Related]
5. Spotlight on pentavalent rotavirus vaccine (RotaTeq) in the prevention of rotavirus gastroenteritis in Europe.
Plosker GL
BioDrugs; 2010 Dec; 24(6):411-4. PubMed ID: 21043548
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya.
Feikin DR; Laserson KF; Ojwando J; Nyambane G; Ssempijja V; Audi A; Nyakundi D; Oyieko J; Dallas MJ; Ciarlet M; Neuzil KM; Breiman RF
Vaccine; 2012 Apr; 30 Suppl 1():A52-60. PubMed ID: 22520137
[TBL] [Abstract][Full Text] [Related]
7. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine.
Breiman RF; Zaman K; Armah G; Sow SO; Anh DD; Victor JC; Hille D; Ciarlet M; Neuzil KM
Vaccine; 2012 Apr; 30 Suppl 1():A24-9. PubMed ID: 22520132
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of an incomplete RotaTeq (RV5) vaccination regimen in preventing rotavirus gastroenteritis in the United States.
Wang FT; Mast TC; Glass RJ; Loughlin J; Seeger JD
Pediatr Infect Dis J; 2013 Mar; 32(3):278-83. PubMed ID: 23014356
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomic spotlight on rotavirus vaccine RIX4414 (Rotarix™) in developed countries.
Plosker GL
Drugs R D; 2012 Dec; 12(4):239-44. PubMed ID: 23017130
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of the oral human attenuated pentavalent rotavirus vaccine (RotaTeq™) postlicensure: a meta-analysis-2006-2020.
Wang Y; Li J; Dai P; Liu P; Zhu F
Expert Rev Vaccines; 2021 Apr; 20(4):437-448. PubMed ID: 33709863
[TBL] [Abstract][Full Text] [Related]
11. Impact of rotavirus vaccination on the burden of acute gastroenteritis in Nagoya city, Japan.
Yoshikawa T; Matsuki T; Sato K; Mizuno M; Shibata M; Hasegawa S; Morita M; Iwasa M; Gopala K; Holl K
Vaccine; 2018 Jan; 36(4):527-534. PubMed ID: 29248263
[TBL] [Abstract][Full Text] [Related]
12. Evidence of herd immunity and sustained impact of rotavirus vaccination on the reduction of rotavirus-related medical encounters among infants from 2006 through 2011 in the United States.
Mast TC; Wang FT; Su S; Seeger JD
Pediatr Infect Dis J; 2015 Jun; 34(6):615-20. PubMed ID: 25831421
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen).
Dennehy PH; Vesikari T; Matson DO; Itzler RF; Dallas MJ; Goveia MG; DiNubile MJ; Heaton PM; Ciarlet M
Hum Vaccin; 2011 May; 7(5):563-8. PubMed ID: 21441783
[TBL] [Abstract][Full Text] [Related]
14. RotaTeq: a three-dose oral pentavalent reassortant rotavirus vaccine.
Chandran A; Santosham M
Expert Rev Vaccines; 2008 Dec; 7(10):1475-80. PubMed ID: 19053204
[TBL] [Abstract][Full Text] [Related]
15. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa.
Tapia MD; Armah G; Breiman RF; Dallas MJ; Lewis KD; Sow SO; Rivers SB; Levine MM; Laserson KF; Feikin DR; Victor JC; Ciarlet M; Neuzil KM; Steele AD
Vaccine; 2012 Apr; 30 Suppl 1():A79-85. PubMed ID: 22520141
[TBL] [Abstract][Full Text] [Related]
16. Reduction in gastroenteritis with the use of pentavalent rotavirus vaccine in a primary practice.
Bégué RE; Perrin K
Pediatrics; 2010 Jul; 126(1):e40-5. PubMed ID: 20587671
[TBL] [Abstract][Full Text] [Related]
17. Public health impact of accelerated immunization against rotavirus infection among children aged less than 6 months in the United States.
Weycker D; Atwood MA; Standaert B; Krishnarajah G
Hum Vaccin Immunother; 2014; 10(7):2032-8. PubMed ID: 25424813
[TBL] [Abstract][Full Text] [Related]
18. Impact of rotavirus vaccination in Australian children below 5 years of age: a database study.
Pendleton A; Galic M; Clarke C; Ng SP; Ledesma E; Ramakrishnan G; Liu Y
Hum Vaccin Immunother; 2013 Aug; 9(8):1617-25. PubMed ID: 23733041
[TBL] [Abstract][Full Text] [Related]
19. Lack of nonspecific protection against all-cause nonrotavirus gastroenteritis by vaccination with orally administered rotavirus vaccine.
Grant L; Watt J; Moulton L; Weatherholtz R; Reid R; Santosham M; O'Brien K
J Pediatr Gastroenterol Nutr; 2013 Jun; 56(6):635-40. PubMed ID: 23343932
[TBL] [Abstract][Full Text] [Related]
20. Real-world impact of rotavirus vaccination.
Patel MM; Steele D; Gentsch JR; Wecker J; Glass RI; Parashar UD
Pediatr Infect Dis J; 2011 Jan; 30(1 Suppl):S1-5. PubMed ID: 21183833
[No Abstract] [Full Text] [Related]
[Next] [New Search]
